Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
4.060
+0.020 (0.50%)
At close: Jul 2, 2026, 4:00 PM EDT
4.020
-0.040 (-0.99%)
After-hours: Jul 2, 2026, 6:58 PM EDT
Protara Therapeutics Employees
Protara Therapeutics had 46 employees as of December 31, 2025. The number of employees increased by 18 or 64.29% compared to the previous year.
Employees
46
Change (1Y)
18
Growth (1Y)
64.29%
Revenue / Employee
n/a
Profits / Employee
-$1,376,239
Market Cap
228.19M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 46 | 18 | 64.29% | 46 | 0 |
| Dec 31, 2024 | 28 | 1 | 3.70% | 28 | 0 |
| Dec 31, 2023 | 27 | 2 | 8.00% | 26 | 1 |
| Dec 31, 2022 | 25 | -6 | -19.35% | 25 | 0 |
| Dec 31, 2021 | 31 | 4 | 14.81% | 31 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Coherus Oncology | 145 |
| Voyager Therapeutics | 141 |
| Nautilus Biotechnology | 127 |
| AC Immune | 122 |
| Alector | 103 |
| Camp4 Therapeutics | 48 |
| NovaBridge Biosciences | 30 |
| Whitehawk Therapeutics | 29 |
TARA News
- 5 weeks ago - Protara Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 6 weeks ago - Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - GlobeNewsWire
- 6 weeks ago - Protara Therapeutics price target raised to $28 from $25 at Oppenheimer - TheFly
- 6 weeks ago - Protara Therapeutics Transcript: KOL event - Transcripts
- 6 weeks ago - Protara Therapeutics Slides: KOL event - Filings
- 6 weeks ago - Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026 - GlobeNewsWire
- 7 weeks ago - Protara announces updated 12-month data from Cohort A of ADVANCED-2 trial - TheFly
- 7 weeks ago - Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC - GlobeNewsWire